EAN consensus statement for management of patients with neurological diseases during the COVID‐19 pandemic

The recent SARS‐CoV‐2 pandemic has posed multiple challenges to the practice of clinical neurology including recognition of emerging neurological complications and management of coexistent neurological diseases. In a fast‐evolving pandemic, evidence‐based studies are lacking in many areas. This paper presents European Academy of Neurology (EAN) expert consensus statements to guide neurologists caring for patients with COVID‐19.

[1]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[2]  A. Pisani,et al.  The international European Academy of Neurology survey on neurological symptoms in patients with COVID‐19 infection , 2020, European journal of neurology.

[3]  T. V. von Oertzen.  COVID‐19 – neurologists stay aware! , 2020, European journal of neurology.

[4]  G. Deuschl,et al.  A call from the European Academy of Neurology on COVID-19 , 2020, The Lancet Neurology.

[5]  H. Hartung,et al.  COVID-19 and management of neuroimmunological disorders , 2020, Nature Reviews Neurology.

[6]  R. Raedt,et al.  Neurological manifestations and neuro‐invasive mechanisms of the severe acute respiratory syndrome coronavirus type 2 , 2020, European journal of neurology.

[7]  O. Zolk,et al.  COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments , 2020, Naunyn-Schmiedeberg's Archives of Pharmacology.

[8]  A. Bar-Or,et al.  COVID-19 and MS disease-modifying therapies , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[9]  K. Schmierer,et al.  The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic , 2020, Multiple Sclerosis and Related Disorders.

[10]  P. Wen,et al.  Neuro-oncology management during the COVID-19 pandemic with a focus on WHO grades III and IV gliomas , 2020, Neuro-oncology.

[11]  G. Tedeschi,et al.  Dealing with immune-mediated neuropathies during COVID-19 outbreak: practical recommendations from the task force of the Italian Society of Neurology (SIN), the Italian Society of Clinical Neurophysiology (SINC) and the Italian Peripheral Nervous System Association (ASNP) , 2020, Neurological Sciences.

[12]  J. Ostrem,et al.  Recommendations for Deep Brain Stimulation Device Management During a Pandemic , 2020, Journal of Parkinson's disease.

[13]  P. Taba,et al.  The need for neurologists in the care of COVID‐19 patients , 2020, European Journal of Neurology.

[14]  Y. Péréon,et al.  Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network , 2020, Revue Neurologique.

[15]  J. Fiehler,et al.  European Society of Minimally Invasive Neurological Therapy (ESMINT) recommendations for optimal interventional neurovascular management in the COVID-19 era , 2020, Journal of NeuroInterventional Surgery.

[16]  N. Juul,et al.  Neuroanesthesia Practice During the COVID-19 Pandemic: Recommendations From Society for Neuroscience in Anesthesiology and Critical Care (SNACC) , 2020, Journal of neurosurgical anesthesiology.

[17]  L. Mao,et al.  Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. , 2020, JAMA neurology.

[18]  W. Kofke,et al.  Anesthetic Management of Endovascular Treatment of Acute Ischemic Stroke During COVID-19 Pandemic: Consensus Statement From Society for Neuroscience in Anesthesiology & Critical Care (SNACC) , 2020, Journal of neurosurgical anesthesiology.

[19]  L. Mao,et al.  Consensus for prevention and management of coronavirus disease 2019 (COVID-19) for neurologists , 2020, Stroke and vascular neurology.

[20]  H. Wiendl,et al.  Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic , 2020, Journal of the Neurological Sciences.

[21]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.